Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

被引：5
|
作者：
Ramalingam, Suresh S. [1 ]
Saka, Hideo [2 ]
Ahn, Myung-Ju [3 ]
Yu, Helena [4 ]
Horn, Leora [5 ]
Hida, Toyoaki [6 ]
Cantarini, Mireille [7 ]
Verheijen, Remy [7 ]
Wessen, Jonathan [7 ]
Oxnard, Geoffrey [8 ]
Ohe, Yuichiro [9 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan
[3] Samsung Med Ctr, Seoul, South Korea
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Aichi Canc Ctr, Nagoya, Aichi, Japan
[7] Astrazeneca, Global Med Dev, Cambridge, England
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Natl Canc Ctr, Tokyo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT034
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.
    Liu, Stephen V.
    Aggarwal, Charu
    Brzezniak, Christina
    Doebele, Robert Charles
    Gerber, David E.
    Gitlitz, Barbara
    Horn, Leora
    Solomon, Benjamin J.
    Stinchcombe, Tom
    Villaruz, Liza Cosca
    West, Howard Jack
    Kroll, Stew
    Pearce, Tillman E.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Kim, Sang-We
    Lee, Ki Hyeong
    Kim, Dong-Wan
    Lee, Yun-Gyoo
    Cho, Eun Kyung
    Lee, Gyeong-won
    Lee, Jong-Seok
    Kim, Joo-Hang
    Kim, Jin-Soo
    Min, Young Joo
    Lee, Sung Sook
    Shin, Sang Won
    Kim, HyeRyun
    Hong, Min Hee
    Ahn, Jin Seok
    Lee, Seoung Oh
    Kim, Sohee
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
    Qian, Xiaoyu
    Guo, Xiaodan
    Li, Ting
    Hu, Wei
    Zhang, Lin
    Wu, Caisheng
    Ye, Feng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study
    Cho, B. C.
    Han, J.
    Kim, S.
    Lee, K.
    Kim, D.
    Lee, Y.
    Lee, G.
    Lee, J.
    Cho, E. K.
    Kim, J.
    Lee, S. S.
    Min, Y. J.
    Kim, J.
    Shin, S. W.
    Kim, H. R.
    Hong, M. H.
    Ahn, J. S.
    Kang, S.
    Kim, S.
    Jang, S. B.
    Choi, S.
    Ahn, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S453
  • [45] Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Wu, Chiao-En
    CANCERS, 2022, 14 (04)
  • [46] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
    Gan, Jiadi
    Huang, Yihua
    Liao, Jun
    Pang, Lanlan
    Fang, Wenfeng
    ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
  • [47] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [48] Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Shah, S.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 328 - 329
  • [49] A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
    de Marinis, F.
    Tu, H.
    Laktionov, K. K.
    Feng, J.
    Poltoratskiy, A.
    Zhao, J.
    Egorova, I.
    Tan, E-H.
    Gottfried, M.
    Lee, V.
    Kowalski, D. M.
    Yang, C-T.
    Srinivasa, B. J.
    Passaro, A.
    Clementi, L.
    Tang, W.
    Huang, D. C-L.
    Cseh, A.
    Zhou, C.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30 : 600 - 600
  • [50] Osimertinib plus Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
    Han, J.
    Sequist, L.
    Ahn, M.
    Cho, B. C.
    Yu, H.
    Kim, S.
    Yang, J. C.
    Lee, J. S.
    Su, W.
    Kowalski, D. M.
    Orlov, S.
    Cantarini, M.
    Ren, S.
    Frewer, P.
    Ou, X.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S227 - S228
12345